# Measurement Precision in CGM Device Production Topic radar · 136 documents · 2021-01-01–2026-10-09 · updated 2026-10-12 Canonical: https://slate.greyb.com/radar/measurement-precision-in-cgm-device-production/innovations ## In one minute ### The technical burden of accuracy is shifting from sensor chemistry to factory-stored duration-based modeling A decisive pattern across the portfolio indicates that manufacturers are no longer attempting to solve electrochemical drift through physical sensor stability alone, but are instead "modeling it out" using individualized device tracking. The dominant 50.7% of the corpus focuses on mapping unique device identifiers (UDIs) to specific performance profiles [1]. This is supported by recent 2026 patents describing systems that collect data on a sensor's environmental exposure prior to use and apply duration-based adjustments to compensate for sensitivity changes during the post-manufacture packaged state [2] [3]. **Why this is worth reading** This represents a fundamental shift in R&D strategy from "better chemistry" to "better logistics data." By using factory-stored parameter libraries to adjust sensor output [4], manufacturers can achieve iCGM-grade precision while utilizing sensors that would otherwise be rejected for drift, effectively turning the digital supply chain into the primary accuracy mechanism. 1. [Manufacturing Automation & Calibration](/radar/measurement-precision-in-cgm-device-production/innovations?bucket=manufacturing_automation_and_calibration) 2. [US12575763B2](/?paper=US12575763B2&utm_source=radar&utm_medium=dashboard) 3. [US2026182868A1](/?paper=US2026182868A1&utm_source=radar&utm_medium=dashboard) 4. [CN112603299B](/?paper=CN112603299B&utm_source=radar&utm_medium=dashboard) ### Factory-stored parameter libraries are replacing manual user calibration A dominant pattern across the portfolio shows the industry shifting the technical burden of sensor accuracy from the patient to factory-stored data libraries. This is evidenced by 51 inventions published between 2021 and 2026 that focus on mapping unique device identifiers (UDIs) to specific performance profiles, effectively using backend databases to compensate for physical sensor variability. Specific mechanisms published in 2025 and 2026 utilize these identifiers to track individual units through manufacturing stages, reading individualized parameters at each step to ensure accuracy without requiring fingerstick reference measurements from the user. ### Individualized sensor tracking replaces physical chemistry as the primary accuracy driver The portfolio demonstrates a decisive shift toward "calibration-free" user experiences by mapping unique device identifiers (UDIs) to specific performance profiles, evidenced by 51 inventions published between 2021 and 2026. This technical trajectory suggests a strategic decision to "model out" electrochemical drift using backend data rather than solving the underlying sensor physics. A 2025 patent describes utilizing unique identifiers to track individual units through manufacturing stages to record individualized parameters, while a 2026 filing introduces duration-based adjustments that compensate for environmental exposure recorded prior to use. ### Scaling production is outstripping quality control, creating a "validation gap" in high-volume lines There is a measurable tension between the massive capital deployment for new facilities—such as Abbott’s €440 million Kilkenny plant and Dexcom’s $325 million Athenry site—and a recurring failure in real-time manufacturing validation. While the portfolio is heavily invested in backend data compensation, the record shows a conspicuous absence of high-volume physical inspection tools; computer vision for quality control represents only 1.5% of the corpus. This gap is likely the technical root of recent regulatory enforcement actions, where units were shipped without required post-sterilization accuracy testing. ### Duration-based modeling is used to "model out" electrochemical drift Rather than solving the fundamental physics of sensor degradation, the record shows a concentrated effort to compensate for it through predictive modeling of environmental and temporal factors. Recent filings from 2026 describe systems that collect data on a sensor's environmental exposure prior to use and determine its wear duration after use to adjust output data accordingly. This approach is mirrored in methods that compensate for temperature effects to reduce the Mean Absolute Relative Deviation (MARD), indicating that accuracy is increasingly treated as a software-defined attribute derived from manufacturing-line history. ### Commercial momentum for non-invasive sensing lacks internal IP support While the portfolio shows significant commercial activity in "needle-free" glucose monitoring—highlighted by a €32.08 million Series B for Sava Technologies in 2026 —there is a conspicuous absence of new internal inventions in this space. The Design & Metrology node contains 20 items of coverage but zero new inventions, suggesting the company is acting as a sophisticated integrator of external components rather than an innovator of measurement physics. This is evidenced by the integration of third-party hardware like the NOVOSENSE NST1002 temperature sensor to stabilize signals. ### The "razor-and-blade" model is being challenged by high-value, long-term hardware integration A concentration of commercial activity and metrology foundations suggests a pivot away from high-volume disposables toward durable, high-precision hardware. This is evidenced by the outsourcing of Afon Technology’s production to the Sony UK Technology Centre and the integration of specialized semiconductor components like the NOVOSENSE NST1002 temperature sensor to stabilize signals. The pursuit of "needle-free" parity and long-term reliability—such as Glucotrack’s three-year implant—forces a move toward consumer-electronics-grade assembly standards rather than traditional medical reagent manufacturing. ### Rapid manufacturing scaling has outpaced internal validation frameworks A significant tension exists between the massive capital commitments for new facilities and recent systemic validation failures recorded in regulatory enforcement actions. While companies are investing hundreds of millions in new plants—such as the €440 million Kilkenny facility and the $325 million Athenry site—public records indicate that high-volume production has led to shipping units without completed post-sterilization accuracy testing. This gap between scale and quality control is further highlighted by recalls linked to hardware failures and unauthorized design changes that occurred during production ramps. ## Overview The continuous glucose monitoring (CGM) sector is shifting its technical center of gravity away from biochemical sensor innovation and toward a data-driven manufacturing architecture that uses individualized device tracking to eliminate user calibration. This transition, led by major incumbents, effectively turns the digital supply chain and factory-stored parameter libraries into the primary competitive moat, as accuracy is increasingly defined by the manufacturer’s ability to model sensor drift rather than eliminate it physically. Manufacturing is shifting the burden of accuracy from the patient to factory-stored parameter libraries. Systemic validation failures in high-volume production are creating a significant regulatory and safety bottleneck. The technical record shows a conspicuous lack of internal innovation in non-invasive sensing despite heavy commercial coverage. Clinical precision is being redefined as a software-defined attribute to compensate for hardware reliability gaps. ## Research ### Algorithmic compensation is being used to mask a hardware reliability crisis Clinical validation records reveal a contradiction: while the portfolio claims high accuracy, there is a lack of proactive technical disclosure regarding Mean Absolute Relative Difference (MARD) errors in diverse populations. Instead, the R&D focus is shifting toward algorithmic compensation and clinical error grids to address underlying sensor instability. This is occurring alongside a significant hardware reliability crisis, including a recall linked to seven patient deaths. ## Market ### Non-invasive sensing relies on external metrology rather than internal IP There is a sharp contradiction between the commercial momentum for non-invasive, "needle-free" glucose monitors and the underlying technical record. While the portfolio contains significant coverage of commercial partnerships and breakthrough designations for non-invasive devices, this specific node contains zero new inventions in the measurement physics itself. Instead, the record shows a reliance on high-end external metrology tools, such as 3D optical surface profilers, and the integration of third-party semiconductor components like the NST1002 temperature sensor to stabilize signals. ## Areas - Manufacturing Automation & Calibration · 69 documents - Clinical Validation & Performance Metrics · 21 documents - Design & Metrology Foundations · 20 documents - Regulatory Compliance & Quality Assurance · 24 documents